Fortress Biotech Inc (FBIO)
Fortress Biotech, Inc. is a biopharmaceutical company listed on NASDAQ under the ticker FBIO. As a common equity security, it represents an ownership interest in the company rather than a fund or other special instrument. Fortress Biotech focuses on the development and commercialization of biopharmaceutical products across a broad range of therapeutic areas. Its marketed portfolio includes dermatology and related treatments such as Emrosi, Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. The company also advances a pipeline that includes intravenous Tramadol, CUTX-101, UNLOXCYT, Olafertinib, CAEL-101, and Triplex, along with early-stage and preclinical candidates spanning oncology, neurology, rare disease, immunology, and gene therapy. Formerly known as Coronado Biosciences, Inc., the company adopted its current name in 2015 and is based in Bay Harbor Islands, Florida.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-FBIO
|
$4.75
|
35.5% Upside
|
Undervalued
|
$11
|
213.4% Upside
|
Bargain
|
Great
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
1.0x
|
0.7x
|
1.8x
|
110.6 M
|
-45.28 M
|
26.2%
|
69.5%
|
1.2
|
—
|
132.2%
|
